MET and lung cancer: Acunzo et al. and Garofalo et al. found that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TNF-related apoptosis-inducing ligand (TRAIL) resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR-222 [16, 17].